Clinical trials
Sexually Transmitted Infections (Not HIV or Hepatitis) clinical trials
Below are recruiting sexually transmitted infections (not hiv or hepatitis) clinical trials, each written for real people, not researchers. We’re tracking 778 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07682961RecruitingPhase 3
Study of new HIV injection vs. standard injectables
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
San Francisco, CaliforniaAges 18 years+ - NCT07650916RecruitingPhase 3
A study of two ultra-long-acting HIV shots
This trial tests a new ultra-long-acting injectable combination of cabotegravir and rilpivirine for people with HIV who already have the virus under control. It aims to see if these shots can keep the virus suppressed with fewer doses.
Phoenix, ArizonaAges 12 years+ - NCT07579741RecruitingPhase 1/Phase 2
Testing JL18008 for HIV Patients Not Recovering Immune Cells
This study tests an experimental drug called JL18008 in people with HIV who have been on stable HIV medications for years but whose immune systems (CD4 cells) haven't recovered as expected. The drug may help boost immune function in these patients.
Beijing, Beijing MunicipalityAges 18–65 - NCT07573943RecruitingPhase 4
ASC22 with Peg-IFN for chronic hepatitis B cure
This study tests whether a combination of two drugs (ASC22 and Peg-IFN) can help people with chronic hepatitis B achieve a functional cure. The goal is to see if this therapy can clear the virus and improve liver health.
Chongqing, Chongqing MunicipalityAges 18–60 - NCT07511218RecruitingPhase 1
Study of AHB-171 for stable chronic hepatitis B
This trial tests a new investigational drug called AHB-171 for people with chronic hepatitis B who are already stable on standard antiviral therapy. It aims to see if the drug is safe and may help control the virus better.
Ch’ang-ch’un, JilinAges 18–65 - NCT07499544RecruitingPhase 3
Testing Libevitug for chronic hepatitis D
This study tests a new drug, Libevitug, for people with chronic hepatitis D (HDV). It aims to see if the drug can help control the virus and improve liver health.
Garden Grove, CaliforniaAges 12–70 - NCT07433387RecruitingPhase 1/Phase 2
Study of a new HIV drug for people not on treatment
This trial tests a new injectable treatment called LP-98 for people with HIV who have never taken HIV medications before. It aims to see if the drug is safe and can help lower the virus in your body.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT07389044RecruitingPhase 1
Testing a new treatment for chronic hepatitis B
This trial tests an investigational drug called IB-001 to see how well it works and how safe it is. It is for healthy volunteers and people with chronic hepatitis B. The goal is to find the best dose and understand side effects.
Hong KongAges 18–70 - NCT07342491RecruitingPhase 1
Testing dasatinib to shrink HIV reservoir
This trial tests whether the drug dasatinib can reduce the hidden HIV reservoir in people who have had their virus well-controlled on HIV medications for a long time. It may help move toward a cure by targeting the cells where HIV hides.
Chicago, IllinoisAges 18 years+ - NCT07275606RecruitingPhase 1/Phase 2
Testing HIV prevention medicine cabotegravir in newborns
This study tests a long-acting injectable HIV prevention medicine called cabotegravir in newborn babies who were exposed to HIV. The goal is to see if it can help protect them from getting HIV.
Parow ValleyAges Up to 1 week - NCT07266831RecruitingPhase 2/Phase 3
New HIV treatment for people not yet on medication
This study tests a new combination medicine for people with HIV who have never taken treatment. It aims to see if it is safe and helps reduce the amount of virus in the blood.
Los Angeles, CaliforniaAges 18 years+ - NCT06906016Recruiting
New blood tests for hepatitis B
This study looks at new blood tests (biomarkers) to better understand chronic hepatitis B and how it affects treatment decisions. It may help doctors find better ways to manage your condition.
Créteil, CréteilAges 18 years+ - NCT06907056RecruitingPhase 4
A study on a simpler HIV medication combination
This study tests if a two-drug HIV regimen (darunavir/cobicistat plus lamivudine) works as well as a standard three-drug regimen in men whose HIV is already well-controlled. If effective, this could mean taking fewer medications.
Mexico City, Mexico CityAges 18–70 - NCT07202546RecruitingPhase 2
New oral HIV drug trial for people new to treatment
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
Bakersfield, CaliforniaAges 18 years+ - NCT07138144RecruitingPhase 4
Switching to a two-drug HIV pill vs. staying on three drugs
This study tests whether switching to a simpler, two-drug HIV pill (dolutegravir/lamivudine) is as safe and effective as staying on a three-drug regimen. It is for people whose HIV is already well-controlled and who are currently taking Biktarvy or Triumeq.
Mexico City, Mexico CityAges 18–70 - NCT07137247Recruiting
How the immune system changes over time in chronic hepatitis B
This study tracks how the immune system works in people with chronic hepatitis B who haven't taken antiviral medication in the last 6 months. It aims to understand the natural history of the infection without treatment.
Guangzhou, GuangdongAges 1–80 - NCT07095192Recruiting
Hepatitis C testing and treatment study in Canada
This study looks at how to make hepatitis C testing and treatment easier to access in Canada. It involves different people, like those at risk, healthcare workers, and policy makers, to find better ways to offer care.
Montreal, QuebecAges 18 years+ - NCT07051187RecruitingPhase 1
WGc0201 for chronic hepatitis B
This trial tests a new drug called WGc0201 in adults with chronic hepatitis B who have controlled their virus with standard antiviral pills. It aims to see if WGc0201 can further reduce hepatitis B surface antigen (HBsAg) levels.
Chengdu, SichuanAges 18–65 - NCT07040319RecruitingPhase 1/Phase 2
Hepatitis C treatment study for pregnant women
This study tests a medicine called glecaprevir/pibrentasvir for pregnant women with hepatitis C, with or without HIV. It aims to see how the medicine works in the body and if it is safe during pregnancy.
Los Angeles, CaliforniaAges 16–45 - NCT06216470RecruitingPhase 2
Testing an antibody treatment for chronic hepatitis B
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
Toronto, OntarioAges 18–65 - NCT06640192RecruitingPhase 2
High-dose HIV drugs to clear hidden virus
This study tests whether giving very high doses of your current HIV meds can flush out hidden HIV that stays in the body even when the virus is undetectable. It might help find a way to reduce or eliminate the reservoir of latent HIV.
Madrid, MadridAges 18–60 - NCT06904820Recruiting
Hepatitis and HIV screening for drug users
This trial tests a convenient way to screen people who use drugs or are in vulnerable situations for hepatitis B, C, and HIV using rapid tests and a liver scanner. The goal is to see if offering these tests in community settings (like shelters or mobile clinics) is acceptable and works well.
LimogesAges 18 years+ - NCT06887036RecruitingPhase 2
Methylene blue for chronic inactive hepatitis B
This trial tests whether a medication called methylene blue can help lower the amount of hepatitis B virus in people with a chronic but inactive infection. It may be an option for people whose virus levels are stable but not fully controlled.
Lugano, Canton TicinoAges 18–79 - NCT06870019Recruiting
Hepatitis C tracker study for unsheltered homelessness
This study tests a simple treatment for Hepatitis C in people experiencing unsheltered homelessness. It aims to help those who are receiving street medicine care and have not been treated before.
Alhambra, CaliforniaAges 18 years+
Hear when a new Sexually Transmitted Infections (Not HIV or Hepatitis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sexually transmitted infections (not hiv or hepatitis)?
- Yes. Clin2 currently lists 778 recruiting sexually transmitted infections (not hiv or hepatitis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sexually transmitted infections (not hiv or hepatitis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sexually transmitted infections (not hiv or hepatitis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.